Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2021-09-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-021-06368-4PMID 34498153PMCID PMC8560558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delay discounting as a predictor of adjuvant endocrine therapy adherence among breast cancer survivors.

  2020cited by this paper
• Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients

  2020cited by this paper
• Factors Associated with Endocrine Therapy Non‐Adherence in Breast Cancer Survivors

  2020cited by this paper
• Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

  2020cited by this paper
• Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors

  2019cited by this paper
• Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture.

  2019cited by this paper
• Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study.

  2019cited by this paper
• Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer

  2019cited by this paper
• Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

  2018cited by this paper
• Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: A Retrospective Review

  2018cited by this paper
• Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

  2018cited by this paper
• Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment

  2017cited by this paper
• Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer

  2017cited by this paper
• Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.

  2017cited by this paper
• Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate

  2016cited by this paper
• Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer

  2016cited by this paper
• Goserelin toxicities and preferences for ovarian suppression method in pre‐menopausal women with breast cancer

  2016cited by this paper
• Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial.

  2016cited by this paper
• Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.

  2016cited by this paper
• Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.

  2015cited by this paper
• Adjuvant ovarian suppression in premenopausal breast cancer.

  2015cited by this paper
• Impact of Fertility Concerns on Tamoxifen Initiation and Persistence.

  2015cited by this paper
• Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.

  2014cited by this paper
• Procurement of shared data instruments for Research Electronic Data Capture (REDCap)

  2013cited by this paper
• Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer

  2011cited by this paper
• Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.

  2007cited by this paper
• Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.

  2000cited by this paper
• Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients

  1999cited by this paper

• Ovarian Function Suppression in HR-Positive, HER2-Positive Breast Cancer: An Exploratory Analysis of the HERA Trial.

  2025cites this paper
• "Anticancer Agents and Their Impact on Breast Reconstruction: A Guide for Plastic Surgeons Based on Systematic Review and Expert Consensus".

  2025cites this paper
• Adherence to adjuvant endocrine therapy including GnRH-analogues and survival: a population-based cohort study

  2025cites this paper
• Extracting Knowledge from Machine Learning Models to Diagnose Breast Cancer

  2025cites this paper
• Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression.

  2025cites this paper
• How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?

  2025cites this paper
• Menopausal Symptom Burden in Premenopausal Breast Cancer Patients: Interaction of Chemotherapy and Ovarian Function Suppression on Tamoxifen Treatment.

  2024cites this paper
• An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management

  2024cites this paper
• Differences in Preferences for Drug Therapy Between Patients with Metastatic Versus Early-Stage Breast Cancer: A Systematic Literature Review

  2024cites this paper
• Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study

  2024cites this paper
• The role of exercise in aromatase inhibitor‐induced arthralgia

  2024cites this paper
• Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer.

  2024cites this paper
• Knowledge and prevalence of common sexually transmitted infections among patients seeking care at selected health facilities in Southern Ghana

  2024cites this paper
• The crosstalk between ubiquitination and endocrine therapy

  2023cites this paper
• Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer.

  2023cites this paper
• New Developments in Systemic Management for High-Risk Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer

  2023cites this paper